Keywords
How to Cite
Abstract
PROINFLAMMATORY CYTOKINES IL-8 AND TNFα IN HENOCH-SCHONLEIN PURPURA IN CHILDREN
Chaika K., Makieieva N.
Henoch-Schonlein purpura (HSP) belongs to a group of systemic vasculitis with predominant damage to small caliber vessels (EULAR/Pres, 2006). Difficulties in diagnosis in the early stages and the likelihood of developing complications leaves HSP in the top of the current issues of pediatrics today. Kidney damage is observed in 20-50% of patients with HSP and leads to complications. In recent years, the question of prognostic markers of progression of HSP remains open. The study involved examination of total of 83 HSP patients aged between 2 and 17, divided into two groups: patients with HSP without nephrotic syndrome (HSPWN, n = 58.35 of which were boys and 23 - girls) and a group of patients with HSP with renal syndrome (HSPN, n = 25.14 of them boys and 11 girls) in acute and remission periods. The Kraskal-Wallis analysis recorded a highly statistically significant H criterion for IL-8 in the acute period (H = 17.421, p = 0.0002) and the remission period (H = 13.035, p = 0.0015). IL-8 levels in both groups of patients with HSP WN and HSPN were significantly higher in the acute period than in the control group, and the difference was statistically significant (p = 0.0004 and p = 0.0002, respectively). No significant difference was found between the medians in both periods regarding TNF-α level (H = 4.136, p = 0.1264; H = 0.133, p = 0.9356).
In the group HSPN in the acute phase, a high IL-8 level in serum has been recorded compared to the group HSPWN. There was no significant difference in TNF-α level in both groups.
Keywords: children, Henoch-Schonlein purpura, Ig-A vasculitis, nephritis.
Абстракт
ПРОЗАПАЛЬНІ ЦИТОКІНИ IL-8 ТА TNFα У ДІТЕЙ ІЗ ПУРПУРОЮ ШЕНЛЯЙН-ГЕНОХА
Чайка Х., Макєєва H.
Пурпура Шенлейна-Геноха (ПШГ) відноситься до групи системних васкулітів з переважним пошкодженням судин малого калібру (EULAR / Pres, 2006). Труднощі в діагностиці на ранніх стадіях та ймовірність розвитку ускладнень залишають ПШГ в числі актуальних проблем педіатрії сьогодні. Ураження нирок спостерігається у 20-50% пацієнтів з ПШГ і призводить до ускладнень. В останні роки питання прогностичних маркерів прогресування ПШГ залишається відкритим. Обстежено 83 пацієнта з ПШГ у віці від 2 до 17 років, які були розділені на дві групи: пацієнти з ПШГ без нефротичного синдрому (ПШГБН, n = 58, 35 з яких були хлопчики і 23 - дівчатка) і група пацієнтів із ПШГ з нирковим синдромом (ПШГН, n = 25, з них 14 хлопчиків і 11 дівчаток) в періоди загострення і ремісії. Аналіз Краскала-Уолліса зареєстрував високий статистично значимий критерій H для IL-8 в гострому періоді (H = 17,421, p = 0,0002) і періоді ремісії (H = 13,035, p = 0,0015). Рівні IL-8 в обох групах пацієнтів з ПШГБН і ПШГН були значно вище в гострому періоді, ніж у контрольній групі, і різниця була статистично значущою (p = 0,0004 і p = 0,0002, відповідно). Не було виявлено суттєвих відмінностей між медіанами в обидва періоди щодо рівня TNF-α (H = 4,136, p = 0,1264; H = 0,133, p = 0,9356).
У групі ПШГН в гострій фазі був зафіксований високий рівень IL-8 в сироватці в порівнянні з групою ПШГБН. Не було значної різниці в рівні TNF-α в обох групах.
Ключові слова: Ig-A васкуліт, діти, пурпура Шенлейна-Геноха, нефрит.
Абстракт
ПРОВОСПАЛИТЕЛЬНЫЕ ЦИТОКИНЫ IL-8 И TNFα У ДЕТЕЙ С ПУРПУРОЙ ШЕНЛЕЙН-ГЕНОХА
Чайка K., Макеева H.
Пурпура Шенлейн-Геноха (ПШГ) относится к группе системных васкулитов с преимущественным повреждением сосудов малого калибра (EULAR / Pres, 2006). Трудности в диагностике на ранних стадиях и вероятность развития осложнений оставляют ПШГ в числе актуальных проблем педиатрии сегодня. Поражение почек наблюдается у 20-50% пациентов с ПШГ и приводит к осложнениям. В последние годы вопрос о прогностических маркерах прогрессирования ПШГ остается открытым. Обследовано 83 пациента с ПШГ в возрасте от 2 до 17 лет, которые были разделены на две группы: пациенты с ПШГ без нефротического синдрома (ПШГБН, n = 58, 35 из которых были мальчики и 23 - девочки) и группа пациенты с ПШГ с почечным синдромом (ПШГН, n = 25, из них 14 мальчиков и 11 девочек) в периоды обострения и ремиссии. Анализ Краскала-Уоллиса зарегистрировал высокий статистически значимый критерий H для IL-8 в остром периоде (H = 17,421, p = 0,0002) и периоде ремиссии (H = 13,035, p= 0,0015). Уровни IL-8 в обеих группах пациентов с ПШГБН и ПШГН были значительно выше в остром периоде, чем в контрольной группе, и разница была статистически значимой (p = 0,0004 и p = 0,0002, соответственно). Не было обнаружено существенных различий между медианами в оба периода в отношении уровня TNF-α (H = 4,136, p = 0,1264; H = 0,133, p = 0,9356). В группе ПШГН в острой фазе был зафиксирован высокий уровень IL-8 в сыворотке по сравнению с группой ПШГБН. Не было значительного различия в уровне TNF-α в обеих группах.
Ключевые слова: Ig-A васкулит, дети,пурпура Шенлейн-Геноха, нефрит.
References
2. Min Yan, Zhan Wang, Na Niu, Jianxia Zhao, Relationship between chronic tonsillitis and Henoch-Schonlein purpura, Int J Clin Exp Med. 2015; 8(8): 14060–14064.
3. Kimura S1, Takeuchi S, Soma Y, Kawakami T., Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura. Clin Exp Dermatol. 2013 Oct; 38(7):730-6.
4. Lin Sun, Biao Xie, Biomarkers identification by a combined clinical and metabonomics analysis in Henoch-Schonlein purpura nephritis children, Oncotarget. 2017 Dec 26; 8(69): 114239–114250.
5. Narangerel Purevdorj Yun Mu Yajun Gu. Clinical significance of the serum biomarker index detection in children with Henoch Schonlein purpura. Clinical Biochemistry. Volume 52, February 2018, Pages 167-170
6. Kimura S1, Takeuchi S, Soma Y, Kawakami T. Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura.Clin Exp Dermatol. 2013 Oct;38(7):730-6.
7. Jaszczura M1, Mizgała-Izworska E2, Świętochowska E3, Machura E4. Serum levels of selected cytokines [interleukin (IL)-17A, IL-18, IL-23] and chemokines (RANTES, IP10) in the acute phase of immunoglobulin A vasculitis in children, Rheumatol Int. 2019 Nov;39(11):1945-1953.
8. Chen T, Guo ZP, Jiao XY, Jia RZ, Zhang YH et al (2011) CCL5, CXCL16, and CX3CL1 are associated with Henoch-Schonlein purpura. Arch Dermatol Res 303(10):715–725.
9. A. Mocanu, I. Miron, S. Diaconescu [et al.] Multifactorial etiopathogeny of Henoch-Schonlein purpura in pediatric age .Revista Romana de Pediatrie. - 2014. - Vol. LXIII (1). - P. 18-21
10. Nalbant S, Koc B, Top C, Kucukardali Y, Baykal Y, Danaci M, Kocer H. Hypersensitivity vasculitis and cytokines. Rheumatol Int. 2002; 22:244–8.
11. Musselwhite L. W. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV / L. W. Musselwhite, V. Sheikh, T. D. Norton // AIDS.- 2011. - Vol. 27, №25(6).- Р. 787-795. 12. Brasier AR, Jamaluddin M, Casola A, Duan W, Shen Q, Garofalo RP. A promoter recruitment mechanism for tumor necrosis factor-α-induced interleukin-8 transcription in type II pulmonary epithelial cells. J Biol Chem. 1998;273:3351–61.
13. Ozen S, Pistorio A, Iusan SM, et al. Criteria for Henoch-Schonlein purpura, childhood polyarteritisnodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria, 2019; Ann Rheum Dis 69:798–806.
14. Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nature Reviews Nephrology.2014;10:563–573. 10.1038/nrneph.2014.126
15. Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, Li Q. Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis. PLoS One. 2016 Nov 30;11(11).
16. Tae-Sun Ha, The role of tumor necrosis factor-α in Henoch-Schönlein purpura, Pediatric Nephrology, February 2005, Volume 20, Issue 2, pp 149–153
17. Y-H Yang, Y-H Huang, Y-L Lin, Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway 2006 May; 144(2): 247–253.
18. Levi M. Two-way interactions between inflammation and coagulation. Cardiovasc Med. 2005 Oct; 15(7):254-9.
19. Dolezalova P, Telekesova P, Nemkova D, Hoza J. Incidence of vasculitis in children in the Czech republic:2-year prospective epidemiology survey. J Rheumatol. 2004;31(11):2295–2299.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.